Despite the turmoil in the Middle East, the market powered to a 30-month high, closing above 12,000 Tuesday. The key driver was a slew of strong earnings reports. The last time we saw Dow 12,000 was on June 19, 2008. Across the board, the major averages were strong. The Dow climbed 148.23 to 12,040.16, S & P 500 rose 21.47 to 1307.59, and the NASDAQ surged 51.11 to 2751.19, as reported in the Wall Street Journal.

Here are just a few stocks that moved the Dow higher:

• Pfizer (PFE) rose $1.00 to $19.22. Fourth-quarter profit tripled from a year ago.

I'm now going to take a brief look at two stocks that were affected by earnings releases earlier today. The two companies are a study in completely different business models: one sells video games, the other sells drugs. Then again, video games are a drug to some, so maybe they aren't so different?

First up: Electronic Arts (ERTS). EA wasn't exciting during the regular session. It closed up fractionally to $15.62; volume was strong, though. And after looking at the extended-hours reaction to the earnings report that was released following the ringing of the bell, it might be understandable why so many players were intent on getting in on the stock.

More inflationary data in the economics and earnings reports matter not at the current time. Less unrest in Egypt, or a lack of escalating unrest, helped out as well. Better than expected auto sales also managed to come through despite awful weather for much of the month in many key markets. All in all, Tuesday was just another strong day for the market and it marked a positive start for the month of February. We got a close above S&P 1300 today!

Here were Tuesday's unofficial closing bell levels:

Dow Jones 12,040.16 +148.23 (1.25%)
S&P 500 1,307.59 +21.47 (1.67%)
Nasdaq 2,751.19 +51.11 (1.89%)

Top Analyst Upgrades & Downgrades

Friday's fourth-quarter GDP numbers offered more evidence that the economy is picking up steam, but one of the biggest obstacles to the recovery remains the stubbornly high unemployment rate. We'll find out whether there's been any movement on that front when employment data for January comes out this week. The Challenger Job-Cut report and ADP employment data are due Wednesday, and the government's unemployment rate on Friday. Another mild increase in jobs is expected, in line with the three-month average, but not enough to significantly reduce the unemployment rate.

Also look for the ISM manufacturing and nonmanufacturing indexes this week, as well as the Chicago PMI and the New York NAPM index. And Fed Chairman Ben Bernanke will speak to the National Press Club on Thursday.

Analyst Upgrades

• Large Cap Pharmaceuticals sector upgraded to Overweight at Wells Fargo.
• Archer Daniels (ADM) upgraded to Outperform from Neutral at Credit Suisse.
• Cypress Semi (CY) upgraded to Buy from Neutral at UBS.
• MFA Financial (MFA) upgraded to Buy from Hold at Jefferies.
• Blackstone (BX) upgraded to Buy from Hold at Jefferies.
• Comerica (CMA) upgraded to Hold from Sell at Citigroup.
• Dollar Tree (DLTR) upgraded to Overweight from Equal Weight at Morgan Stanley.
• NuVasive (NUVA) upgraded to Outperform from Market Perform at Leerink.
• Cogdell Spencer (CSA) upgraded to Buy from Hold at Jefferies.
• Hersha Hospitality (HT) upgraded to Hold from Underperform at Jefferies.
• G&K Services (GKSR) upgraded to Outperform from Neutral at RW Baird.
• Graham Packaging (GRM) upgraded to Buy from Neutral at Goldman.
• Shaw (SJR) upgraded to Neutral from Underperform at BofA/Merrill.

Barron's is forecasting a 10% rise in stock prices in 2011 led by big cap stocks. They argue that the big caps have lagged the market for the past decade and are now poised to take the lead, as reported by CNBC.com.

Here are their top ten picks for this year: Exxon Mobil (XOM), Walmart (WMT), Pfizer (PFE), JPMorgan Chase (JPM), General Motors (GM), Cisco Systems (CSCO), United Continental Holdings (UAL), Barrack Gold (ABX), Entergy (ETR), and PepsiCo (PEP).

Ben Bernanke's explanation and defense, or lack thereof to many, about his version of QE2, managed to dominate many key themes today. Gold was hitting fresh highs and European woes were discounted again. We are seeing the risk trade come in full force, although many of the sectors were soft. Late-day selling in the DJIA and S&P500 made for a close in the red, but this was close to red and black for most of the afternoon session after a fairly weak open.

Here are today's unofficial closing bell levels:

Dow Jones 11,362.19 -19.90 (-0.17%)
S&P 500 1,223.12 -1.59 (-0.13%)
Nasdaq 2,594.92 +3.46 (0.13%)

Top Analyst Calls

Analyst Upgrades

• Research In Motion (RIMM) to buy from hold at Jefferies.
• Citigroup (C) to buy from hold at ISI Group.
• Integrated Silicon (ISSI) to buy from hold at Auriga.
• Kinross Gold (KGC) to outperform from neutral at Credit Suisse.

Today is election day. Currently, intrade.com is projecting a 97% chance that the Republicans will take control of the House of Representatives and a 48% chance that they will win the Senate. What could a landslide win for the Republican Party mean for the stock market?

Some observers are suggesting that gridlock in Washington, along with a more business friendly atmosphere, could be a catalyst for stock prices to rise. This, however, is offset by concerns about cuts in government spending. The private economy is sputtering, and near-term spending cuts could have a detrimental effect on the recovery. Therefore, instead of focusing on the broader market, investors may want to look at some specific sectors that may benefit from a Republican victory.

Three interesting areas are oil services, financials, and healthcare. The thinking is that some of the regulatory headwinds facing these sectors may be lifted if the political atmosphere in Washington D.C. changes. Some observers believe that a Republican-led House of Representatives will be able to chip away at some of the Obamacare legislation. This should benefit large pharmaceutical companies such as Merck (MRK) and Pfizer (PFE).

Pharmaceutical firm Pfizer (PFE) announced third-quarter earnings this morning, reporting that large charges pulled its profit 70% lower than a year ago. The pfunnily spelled pfarmaceutical pfirm reported that net income came in at $866 million, or 11 cents per share, down from $2.88 billion, or 43 cents per share, a year ago.

Taking one-time items out of the equation, Pfizer earned $4.37 billion, or 54 cents per share, topping the consensus estimate by three cents.

Analyst Upgrades

• Macquarie upgraded Intel (INTC) to outperform from neutral and Advanced Micro (AMD) to neutral from underperform.
• Pfizer (PFE) was upgraded to outperform from market perform at Bernstein.
• Capstead Mortgage (CMO) was upgraded to outperform from market perform at FBR Capital.
• Oppenheimer upgraded Halliburton (HAL) to outperform from perform.
• Gilead (GILD) was upgraded to outperform from sector perform at RBC Capital.
• Skilled Healthcare (SKH) was upgraded to outperform from market perform at JMP Securities.
• Citigroup upgraded CapitalSource (CSE) to buy from hold.

It will be a busy week. Republicans are poised to gain control of the House of Representatives and gain governorships in Tuesday's mid-term elections. Also, the Federal Reserve is expected to announce another round of quantitative easing Wednesday, following the FOMC meeting. Major retailers are scheduled to report October same-store sales Thursday, while the October unemployment rate, announced on Friday, is expected to remain at 9.6%.

Toyota's (TM) fiscal second-quarter results will be one of the highlights on the earnings front this week. After three periods of way underestimating Toyota's earnings, have the analysts surveyed by Thomson Reuters got it right this time? The stock sure could use a boost. Teva Pharmaceuticals (TEVA) is in a similar situation; i.e., high expectations for this week's quarterly results but a stock in need of a boost. Marathon (MRO) and Starbucks (SBUX) are also expected to post strong earnings growth this week, but both stocks are riding high.

Analyst Upgrades

• Citigroup upgraded Mosaic (MOS) to buy from hold and raised its price target to $78 from $64 citing improving ag fundamentals and the potential for BHP (BHP) to issue a higher bid for Potash (POT), which Citi feels would bode well for Mosaic.
• Cowen upgraded VMware (VMW) to outperform from neutral, citing recent share weakness and the company's significant growth opportunity.
• Citigroup upgraded CareFusion (CFN) with a $29 price target, citing valuation and the potential for margin expansion.
• Pfizer (PFE) was upgraded to outperform from neutral at Cowen.
• Juniper (JNPR) was upgraded to outperform from perform at Oppenheimer.
• Stryker (SYK) was upgraded to buy from gradually accumulate at Soleil.

Stocks started the week off in the red on a key tech downgrade, and as the U.S. dollar rose against some key currencies. Frankly, today felt like a day where the real answer was "more sellers than buyers" over a key catalyst, even considering a EU terror alert. The end of the TARP program marked more sentiment than any real event.

Here were the unofficial closing bell levels:

Dow Jones 10,751.27 -78.41 (-0.72%)
S&P 500 1,137.03 -9.21 (-0.80%)
Nasdaq 2,344.52 -26.23 (-1.11%)

Top Analyst Calls
Best & Worst DJIA Stocks

Bristol-Myers Squibb (BMY - option chain) shares are rising today after the release of a study which shows that an experimental blood-thinning drug co-produced by BMY and Pfizer (PFE) cut the rate of strokes among people with abnormal heartbeats by more than 50% versus aspirin. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on BMY.

BMY opened this morning at $26.11. So far today the stock has hit a low of $26.00 and a high of $26.34. As of 12:25, BMY is trading at $26.20 up 0.35 (1.3%). The chart for BMY looks bullish and S&P gives BMY a positive 4 STARS (out of 5) buy ranking.